| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | -16.25 M USD | -1.30 M USD | -2.06 M USD | -581189 USD | — |
| Depreciation & Amortization | — | — | — | — | — |
| Stock-Based Compensation | 891000 USD | 21000 USD | — | — | — |
| Capital Expenditures | 8000 USD | — | — | — | — |
| Cash Flow from Investing | -2.01 M USD | 2.97 M USD | 185.60 M USD | 33447 USD | — |
| Cash Flow from Financing | 19.84 M USD | -1.66 M USD | -183.72 M USD | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | 3.25 M USD | 184.85 M USD | — | — |
| Free Cash Flow | -16.26 M USD | — | — | — | — |
Profusa, Inc. is a clinical-stage digital health and medical technology company developing biosensing solutions to improve health outcomes for patients with various diseases and conditions. Its innovative technology features bioengineered sensors designed to integrate with the body, enabling continuous detection and transmission of actionable, clinical-grade data for personal and medical applications. A key product, the Lumee Oxygen Platform, available in the European Union, provides reliable long-term monitoring of tissue oxygen levels in targeted body regions. Profusa also engages in biofeedback services supporting chronic disease management and healthy living. Operating within the electronic technology sector, particularly semiconductors for medical applications, the company addresses needs in healthcare monitoring and diagnostics. Headquartered in Berkeley, California, Profusa, Inc. focuses on advancing implantable sensor technologies to deliver real-time physiological insights, playing a role in the growing digital health market by bridging personal wellness and professional medical care.